GeneralConnection.com ➔ Dictionary
Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
Oral infigratinib boosts growth velocity in achondroplasia study - 2 Minute Medicine
Arvada boy with dwarfism thrives at school thanks to doctor who goes the extra mile - KUSA.com
Ribomic’s Achondroplasia Drug Hits Phase II Height-Growth Goal, Paving Way for Phase III - TipRanks
FDA Issues Historic Approval for Navepegritide in Achondroplasia - Contemporary Pediatrics
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
FDA Approves Navepegritide for Children With Achondroplasia - Pharmacy Times
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
New treatment gives hope to children with achondroplasia - Loma Linda University
BridgeBio drug for genetic cause of dwarfism succeeds in key study - statnews.com
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
Oral Infigratinib Therapy in Children with Achondroplasia - The New England Journal of Medicine
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
TYRA: Oral Dabogratinib targets blockbuster potential in UTUC, NMIBC, and achondroplasia with pivotal data ahead - TradingView
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Answers
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewswire
FDA Okays Weekly Option in Achondroplasia - Conexiant
Doctor helps Colorado boy with dwarfism thrive at school - KUSA.com
TYRA: Oral dabogratinib targets blockbuster opportunities in UTUC, NMIBC, and achondroplasia - TradingView
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord Pharma
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCPLive
Pregnancy and Delivery in a Woman With Achondroplasia: A Multidisciplinary Management Approach - Cureus
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia - Contemporary Pediatrics
The latest on navepegritide for children with achondroplasia, with Carlos Bacino, MD - Contemporary Pediatrics
Ascendis wins FDA approval of dwarfism drug - BioPharma Dive
Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial - HCPLive
FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia - Indian Pharma Post
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
FDA Approves Once-Weekly Yuviwel® (Navepegritide) For Children With Achondroplasia Aged 2 Years And Older - TradingView
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - MarketBeat
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
TYRA: FGFR3-targeted trials advance in NMIBC, achondroplasia, and UTUC, with key data expected this year - TradingView
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Achondroplasia: Update on diagnosis, follow-up and treatment - Anales de Pediatría
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
Inside pharma’s race to deliver new treatments for dwarfism - PharmaVoice
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia - TipRanks
Management of achondroplasia in pregnancy - FIGO.org
Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena
Ascendis scores FDA approval for weekly dwarfism drug - pharmaphorum
FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
FDA approves once-weekly growth drug for children with achondroplasia - Stock Titan
New investigational therapy shows promise for treating skeletal disorders - Drug Target Review
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
Results of Pivotal ApproaCH Trial of TransCon® CNP - GlobeNewswire
Ribomic’s RBM-007 ready for phase III in achondroplasia - bioworld.com
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia - Contemporary Pediatrics
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older - GlobeNewswire
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings - PR Newswire
BioMarin at Leerink Global Healthcare: Strategic Growth Focus - Investing.com
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Yahoo Finance
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio data for dwarfism drug sets up showdown with BioMarin's Voxzogo - FirstWord Pharma
FDA approves Ascendis’ once-weekly achondroplasia treatment By Investing.com - Investing.com Nigeria
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
Postoperative Rehabilitation Following Total Hip Arthroplasty in Achondroplasia: A Case Report Focused on Dislocation Prevention and Environmental Simulation - Cureus
FDA delays decision on Ascendis' dwarfism prospect by 3 months - Fierce Biotech
FDA Approves Navepegritide for Achondroplasia in Children - Medical Dialogues
FDA pushes back Ascendis’ dwarfism drug decision date by three months - Endpoints News
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
Ascendis Pharma Achondroplasia Data Highlights Emerging Rare Disease Franchise Potential - simplywall.st
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
Using Genetics to Improve Hypochondroplasia Diagnosis - BioMarin Pharmaceutical
RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older - BioSpace
Ascendis reports strong results for achondroplasia combination therapy - Investing.com
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
Here we grow: chondrocytes’ behavior reveals novel targets for bone growth disorders - 大阪大学
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - Yahoo Finance
Oral drug helps achondroplasia patients grow faster, improve body proportions - Stock Titan
Driving Progress for Children with Achondroplasia - BioMarin Pharmaceutical
Peter Dinklage shares achondroplasia struggle: 'My whole life I've had stares' - The News International
BridgeBio reports breakthrough results in Phase 3 achondroplasia trial - Indian Pharma Post
Patients With Achondroplasia in Slovakia Will Soon Have Access to Voxzogo - NAVLIN DAILY
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Yahoo Finance
BridgeBio’s dwarfism drug succeeds in Phase 3, adding to recent late-stage wins - Endpoints News
MAA Submission to EMA: Ascendis Seeks EU Approval for TransCon CNP to Treat Achondroplasia - Stock Titan
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com Australia
New therapeutic frontiers in the management of achondroplasia - News-Medical
AIFA Approves Reimbursement for BioMarin’s Voxzogo to Include Patients Aged 4 Months to 2 Years with Achondroplasia - NAVLIN DAILY
Biomarin Receives Health Canada Notice Of Compliance With Conditions For Voxzogo®, For Achondroplasia - TradingView
BioMarin receives Health Canada Notice of Compliance with conditions for VOXZOGO®, for Achondroplasia - Newswire Canada
Cellular pathways and treatment frontiers of achondroplasia - EurekAlert!
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
achondropasia,   achondropalsia,   achondroplassia,   achondeoplasia,   achondrop;asia,   achondroplsia,   achondroplasiia,   achonndroplasia,   achondroplasi,   avhondroplasia,   cahondroplasia,   achondrplasia,   achondrolasia,   acohndroplasia,   achobdroplasia,   achindroplasia,   acgondroplasia,   aachondroplasia,   achondroplsaia,   achondroplssia,   axhondroplasia,   achondtoplasia,   acchondroplasia,   achondoplasia,   achondroplaasia,   achodroplasia,   achondroplasai,   ahcondroplasia,   achondroplaisa,   achnodroplasia,   achondrpplasia,   achondorplasia,   achondroplaia,   achndroplasia,   achonroplasia,   ahondroplasia,   achondrpolasia,   achondroplasiaa,   achpndroplasia,   achondroplasa,   achondriplasia,   achondrolpasia,   achondropladia,   achonrdoplasia,   achondroolasia,   achondro[lasia,   achomdroplasia,   schondroplasia,   achondroplasis,   achodnroplasia,   achonfroplasia,   achondroplasoa,   achondropplasia,   achondrroplasia,   achhondroplasia,   achondropllasia,   achondroplaaia,   acjondroplasia,   chondroplasia,   achonddroplasia,   acondroplasia,   achondropkasia,   achonsroplasia,   achondrooplasia,   achondroplasua,   achoondroplasia
Words Starting with Letter - 'A'
achromycin achy achylia
achylia gastrica acicula acicular
aciculate acid acid anhydrides
acid dye acid halide acid head
acid hydrogen acid precipitation acid rain
acid rock acid test acid value
acid-base balance acid-base equilibrium acid-base indicator
acid-fast acid-forming acid-loving
« Go to Page 40            Go to Page 42 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z